WO1996011013A1 - Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies - Google Patents
Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies Download PDFInfo
- Publication number
- WO1996011013A1 WO1996011013A1 PCT/US1995/011964 US9511964W WO9611013A1 WO 1996011013 A1 WO1996011013 A1 WO 1996011013A1 US 9511964 W US9511964 W US 9511964W WO 9611013 A1 WO9611013 A1 WO 9611013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cdr
- antibody
- region
- monoclonal antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69535755T DE69535755D1 (en) | 1994-10-05 | 1995-09-28 | CDR-EXCHANGED TYPE III ANTI-CEA HUMANIZED MONOCLONAL MOUSE ANTIBODY |
JP51258896A JP3437580B2 (en) | 1994-10-05 | 1995-09-28 | Type III anti-CEA humanized mouse monoclonal antibody grafted with CDR |
AU37196/95A AU689331C (en) | 1994-10-05 | 1995-09-28 | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
CA2200868A CA2200868C (en) | 1994-10-05 | 1995-09-28 | Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies |
EP95935020A EP0783313B1 (en) | 1994-10-05 | 1995-09-28 | Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/318,157 US5874540A (en) | 1994-10-05 | 1994-10-05 | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
US08/318,157 | 1994-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996011013A1 true WO1996011013A1 (en) | 1996-04-18 |
Family
ID=23236916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/011964 WO1996011013A1 (en) | 1994-10-05 | 1995-09-28 | Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies |
Country Status (8)
Country | Link |
---|---|
US (3) | US5874540A (en) |
EP (3) | EP0783313B1 (en) |
JP (3) | JP3437580B2 (en) |
AT (2) | ATE464906T1 (en) |
CA (1) | CA2200868C (en) |
DE (2) | DE69535755D1 (en) |
ES (1) | ES2307294T3 (en) |
WO (1) | WO1996011013A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997042329A1 (en) * | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
WO1999043817A1 (en) * | 1998-02-25 | 1999-09-02 | The Dow Chemical Company | High affinity humanized anti-cea monoclonal antibodies |
EP0939653A1 (en) * | 1996-03-20 | 1999-09-08 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
WO2002002738A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
WO2002002783A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Expression vectors |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
US7803372B2 (en) | 2002-10-08 | 2010-09-28 | Immunomedics, Inc. | Antibody therapy |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
EP3066470A4 (en) * | 2013-11-05 | 2017-05-31 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
US10316104B2 (en) | 2011-04-29 | 2019-06-11 | Roche Glycart Ag | Immunoconjugates |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US6703488B1 (en) * | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US20030099629A1 (en) * | 1999-03-11 | 2003-05-29 | Immunomedics, Inc. | Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase |
US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
CA2417185A1 (en) * | 2000-07-25 | 2002-01-31 | Shui-On Leung | Multivalent target binding protein |
US20020165360A1 (en) * | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
WO2002078638A2 (en) * | 2001-03-30 | 2002-10-10 | University Of Massachusetts | Morpholino imaging and therapy |
EP1444267B1 (en) * | 2001-10-15 | 2016-08-10 | Immunomedics, Inc. | Affinity enhancement agents |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP2865688A1 (en) | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
US20040018557A1 (en) * | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
DE60325184D1 (en) | 2002-03-01 | 2009-01-22 | Immunomedics Inc | RS7 ANTIBODY |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
WO2003101495A1 (en) * | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
KR20050073488A (en) * | 2002-10-08 | 2005-07-13 | 이뮤노메딕스, 인코오포레이티드 | Combination therapy with class Ⅲ anti-CEA monoclonal antibodies and therapeutic agents |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
WO2004054622A1 (en) * | 2002-12-13 | 2004-07-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
JP5026072B2 (en) * | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | Multispecific carrier of bispecific antibody |
JP2007524649A (en) * | 2003-07-29 | 2007-08-30 | イミューノメディクス、インコーポレイテッド | Fluorinated carbohydrate complex |
US6878531B1 (en) * | 2003-11-10 | 2005-04-12 | Medical College Of Georgia Research Institute | Method for multiple site-directed mutagenesis |
US20050132544A1 (en) * | 2003-12-23 | 2005-06-23 | Jayshree Seth | Split hook fastener |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US20110171126A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma |
US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
US20060127311A1 (en) * | 2004-11-17 | 2006-06-15 | Duke University | Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
CN101534865A (en) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
WO2008069999A2 (en) | 2006-12-01 | 2008-06-12 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases |
EP2288715B1 (en) | 2008-04-11 | 2014-09-24 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
AU2009282830B2 (en) * | 2008-08-20 | 2013-11-28 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
JP2012504961A (en) | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | MUC1 * antibody |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
EP3243527B1 (en) | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
EP2506881B1 (en) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
CN101928347B (en) * | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
BR112013009083B1 (en) * | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | HUMAN ANTIBODIES TO ONCOSTATIN M, ITS MANUFACTURING PROCESS, ANTIGEN-BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION, ISOLATED POLYNUCLEOTIDE, RECOMBINANT HOST CELL STABLELY TRANSFORMED OR TRANSFECTED |
JP2012171088A (en) * | 2011-02-24 | 2012-09-10 | Olympus Corp | Master operation input device, and master-slave manipulator |
NZ614125A (en) * | 2011-03-02 | 2015-07-31 | Roche Glycart Ag | Cea antibodies |
CA2853138A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
HRP20220399T1 (en) | 2012-12-13 | 2022-05-13 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
MX2016010683A (en) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Disease therapy by inducing immune response to trop-2 expressing cells. |
CN106029098A (en) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | Humanized RFB4 anti-CD22 antibody |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
US10442863B2 (en) | 2014-09-08 | 2019-10-15 | Lutana Gmbh | Construct for the delivery of a molecule into the cytoplasm of a cell |
CN106999517A (en) | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | The new adjuvant purposes of antibody drug conjugate |
JP6895890B2 (en) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | Humanized anti-MUC1 * antibody |
EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
WO2016210108A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
SI3316885T1 (en) | 2015-07-01 | 2021-09-30 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US10618978B2 (en) | 2015-09-30 | 2020-04-14 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
ES2819870T3 (en) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Modified J-chain binding molecules |
CA3011372A1 (en) | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
WO2017189279A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
WO2018183041A1 (en) | 2017-03-27 | 2018-10-04 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
MX2021003184A (en) | 2018-09-26 | 2021-08-11 | Ascendis Pharma As | Degradable hyaluronic acid hydrogels. |
CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
AR119382A1 (en) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
CN114630684A (en) | 2019-09-03 | 2022-06-14 | 博尔特生物治疗药物有限公司 | Aminoquinoline compounds, immunoconjugates and uses thereof |
AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
TW202128226A (en) | 2019-10-25 | 2021-08-01 | 美商博特生物治療公司 | Thienoazepine immunoconjugates, and uses thereof |
WO2021226440A1 (en) | 2020-05-08 | 2021-11-11 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
JP2023533173A (en) | 2020-07-09 | 2023-08-02 | エフ. ホフマン-ラ ロシュ アーゲー | Concentrated compositions of proteins, their preparation and their use |
CR20230076A (en) | 2020-07-10 | 2023-03-13 | Hoffmann La Roche | Antibodies which bind to cancer cells and target radionuclides to said cells |
CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
EP4097486A4 (en) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
CA3188862A1 (en) | 2020-08-20 | 2022-02-24 | Carl Alexander Kamb | Compositions and methods for treating mesothelin positive cancers |
WO2022125891A2 (en) | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
AU2022207615A1 (en) | 2021-01-12 | 2023-07-13 | F. Hoffmann-La Roche Ag | Split antibodies which bind to cancer cells and target radionuclides to said cells |
EP4277668A1 (en) | 2021-01-13 | 2023-11-22 | F. Hoffmann-La Roche AG | Combination therapy |
IL306114A (en) | 2021-03-26 | 2023-11-01 | Bolt Biotherapeutics Inc | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
WO2022204536A1 (en) | 2021-03-26 | 2022-09-29 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
EP4342497A1 (en) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antibody having reduced binding affinity for antigen |
WO2023016488A1 (en) | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | Microtubule inhibitor-based antibody-drug conjugate |
CN117881431A (en) | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | Antibody-conjugated drug conjugated by cleavable linker |
WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323805A2 (en) * | 1988-01-05 | 1989-07-12 | Buchegger, Franz | Novel antibodies |
WO1992001059A1 (en) * | 1990-07-05 | 1992-01-23 | Celltech Limited | Cdr grafted anti-cea antibodies and their production |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5081235A (en) * | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2206447T3 (en) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
ATE306930T1 (en) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | IMMUNE CONJUGATES AND HUMAN ANTIBODIES SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS |
IL115177A0 (en) * | 1994-09-16 | 1995-12-31 | Immunomedics Inc | Phosphorus-32 labeling of antibodies for cancer therapy |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
-
1994
- 1994-10-05 US US08/318,157 patent/US5874540A/en not_active Expired - Lifetime
-
1995
- 1995-09-28 AT AT06076426T patent/ATE464906T1/en not_active IP Right Cessation
- 1995-09-28 JP JP51258896A patent/JP3437580B2/en not_active Expired - Fee Related
- 1995-09-28 WO PCT/US1995/011964 patent/WO1996011013A1/en active Application Filing
- 1995-09-28 EP EP95935020A patent/EP0783313B1/en not_active Expired - Lifetime
- 1995-09-28 EP EP06076426A patent/EP1736163B1/en not_active Expired - Lifetime
- 1995-09-28 DE DE69535755T patent/DE69535755D1/en not_active Expired - Lifetime
- 1995-09-28 AT AT95935020T patent/ATE395068T1/en not_active IP Right Cessation
- 1995-09-28 CA CA2200868A patent/CA2200868C/en not_active Expired - Lifetime
- 1995-09-28 EP EP08008840.4A patent/EP1967528B1/en not_active Expired - Lifetime
- 1995-09-28 ES ES95935020T patent/ES2307294T3/en not_active Expired - Lifetime
- 1995-09-28 DE DE69536072T patent/DE69536072D1/en not_active Expired - Lifetime
-
1999
- 1999-02-22 US US09/253,794 patent/US6676924B2/en not_active Expired - Fee Related
-
2001
- 2001-11-22 JP JP2001357367A patent/JP2002218990A/en active Pending
-
2004
- 2004-01-13 US US10/755,382 patent/US20050089538A1/en not_active Abandoned
-
2009
- 2009-11-16 JP JP2009260907A patent/JP5183611B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323805A2 (en) * | 1988-01-05 | 1989-07-12 | Buchegger, Franz | Novel antibodies |
WO1992001059A1 (en) * | 1990-07-05 | 1992-01-23 | Celltech Limited | Cdr grafted anti-cea antibodies and their production |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6730300B2 (en) | 1996-03-20 | 2004-05-04 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
US7348419B2 (en) | 1996-03-20 | 2008-03-25 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications |
EP0939653A1 (en) * | 1996-03-20 | 1999-09-08 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
EP0939653A4 (en) * | 1996-03-20 | 2001-02-14 | Immunomedics Inc | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
US6903203B2 (en) | 1996-05-04 | 2005-06-07 | Astrazeneca Uk Ltd. | Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use |
US6277599B1 (en) | 1996-05-04 | 2001-08-21 | Zeneca Limited | Anti-CEA antibody designated 806.077, hybridoma and method of manufacture |
WO1997042329A1 (en) * | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
WO1999043817A1 (en) * | 1998-02-25 | 1999-09-02 | The Dow Chemical Company | High affinity humanized anti-cea monoclonal antibodies |
WO2002002738A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
WO2002002783A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Expression vectors |
WO2002002738A3 (en) * | 2000-07-03 | 2002-05-30 | Gala Design Inc | Host cells containing multiple integrating vectors |
WO2002002783A3 (en) * | 2000-07-03 | 2003-01-16 | Gala Design Inc | Expression vectors |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
US7378273B2 (en) | 2000-07-03 | 2008-05-27 | Gala Design, Inc. | Expression vectors |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
US8216572B2 (en) | 2002-10-08 | 2012-07-10 | Immunomedics, Inc. | Antibody therapy |
US8062636B2 (en) | 2002-10-08 | 2011-11-22 | Immunomedics, Inc. | Antibody therapy |
US7919090B2 (en) | 2002-10-08 | 2011-04-05 | Immunomedics, Inc. | Antibody therapy |
US7803372B2 (en) | 2002-10-08 | 2010-09-28 | Immunomedics, Inc. | Antibody therapy |
US8535676B2 (en) | 2002-10-08 | 2013-09-17 | Immunomedics, Inc. | Antibody therapy |
US8778342B2 (en) | 2002-10-08 | 2014-07-15 | Immunomedics, Inc. | Antibody therapy |
US10316104B2 (en) | 2011-04-29 | 2019-06-11 | Roche Glycart Ag | Immunoconjugates |
US11130822B2 (en) | 2011-04-29 | 2021-09-28 | Roche Glycart Ag | Immunoconjugates |
EP3066470A4 (en) * | 2013-11-05 | 2017-05-31 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Also Published As
Publication number | Publication date |
---|---|
DE69536072D1 (en) | 2010-06-02 |
AU3719695A (en) | 1996-05-02 |
EP0783313A4 (en) | 2005-01-12 |
EP1967528B1 (en) | 2015-03-04 |
JP2010075190A (en) | 2010-04-08 |
US6676924B2 (en) | 2004-01-13 |
CA2200868A1 (en) | 1996-04-18 |
US20020018750A1 (en) | 2002-02-14 |
EP1967528A2 (en) | 2008-09-10 |
JP2002218990A (en) | 2002-08-06 |
ES2307294T3 (en) | 2008-11-16 |
JP3437580B2 (en) | 2003-08-18 |
EP0783313A1 (en) | 1997-07-16 |
JP5183611B2 (en) | 2013-04-17 |
ATE395068T1 (en) | 2008-05-15 |
US20050089538A1 (en) | 2005-04-28 |
EP1967528A3 (en) | 2008-12-17 |
AU689331B2 (en) | 1998-03-26 |
ATE464906T1 (en) | 2010-05-15 |
EP0783313B1 (en) | 2008-05-14 |
DE69535755D1 (en) | 2008-06-26 |
JPH10508466A (en) | 1998-08-25 |
EP1736163A1 (en) | 2006-12-27 |
US5874540A (en) | 1999-02-23 |
EP1736163B1 (en) | 2010-04-21 |
CA2200868C (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5874540A (en) | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies | |
US6417337B1 (en) | High affinity humanized anti-CEA monoclonal antibodies | |
EP0771208B1 (en) | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells | |
JP3904238B2 (en) | Glycosylated humanized B cell specific antibody | |
US6307026B1 (en) | Humanized antibodies directed against A33 antigen | |
AU675268B2 (en) | Humanised antibodies directed against A33 antigen | |
US5993813A (en) | Family of high affinity, modified antibodies for cancer treatment | |
US6051225A (en) | Family of high affinity, modified antibodies for cancer treatment | |
US5645817A (en) | Granulocyte-binding antibody constructs, their preparation and use | |
AU6338898A (en) | High affinity humanized anti-cea monoclonal antibodies | |
AU689331C (en) | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies | |
AU723073B2 (en) | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2200868 Country of ref document: CA Ref country code: CA Ref document number: 2200868 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995935020 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995935020 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |